Thyroid Eye Disease and Graves’ Programs

Advancing Differentiated Anti-IGF-1R and Anti-TSHR Antibodies

Viridian is currently investigating a portfolio of potentially transformative monoclonal antibodies for the potential treatment of thyroid eye disease (TED) and Graves’ disease.

Insulin-like growth factor-1 receptor (IGF-1R), is a transmembrane receptor that plays a role in development, metabolism, and immune regulation, and is a clinically and commercially validated target for the treatment of TED.

Thyroid stimulating hormone receptor (TSHR) plays a central role in Graves’ disease and is also implicated in the development of TED. Research suggests a functional relationship between IGF-1R and TSHR signaling in TED, although the underlying mechanisms continue to be studied.

Viridian is advancing a potentially differentiated anti-IGF-1R antibody and an anti-TSHR antibody. We believe these programs have the potential to meaningfully improve treatment options for patients with TED and Graves’ disease.

Elegrobart

VRDN-292

Administration

Self-administered Subcutaneous Injection

Self-administered Subcutaneous Injection

Mechanism

Full Antagonist

Undisclosed

Phase of Development

Phase 3 - BLA submission anticipated Q1 2027

Preclinical - Phase 1 study initiation anticipated Q4 2026

Proposed Treatment Regimen

Dosing every eight or four weeks

Undetermined

Potential Indication

TED

Graves' Disease

TED Program Details

Elegrobart is an investigational, subcutaneously delivered, half‑life‑extended, monoclonal antibody targeting the insulin‑like growth factor‑1 receptor (IGF‑1R). Elegrobart is a full antagonist of IGF-1R and was engineered to have a longer half-life. Elegrobart is designed to be a low volume, infrequently dosed subcutaneous IGF-1R for TED, which we believe has the potential to preserve the efficacy of anti-IGF-1Rs in TED, improve tolerability, and improve convenience for patients with subcutaneous delivery.

We reported positive topline results for elegrobart from two pivotal phase 3 clinical trials, REVEAL-1 and REVEAL-2, for people living with active and chronic TED, respectively.

ElegrobartVRDN-003 is a potential best-in-class subcutaneous monoclonal antibody targeting IGF-1R. VRDN-003 has the same binding domain as its parent molecule, VRDN-001, and was engineered to have a longer half-life. VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience and potentially improving safety. Viridian is on track to initiate two phase 3 clinical trials of VRDN-003 in August 2024.

Viridian’s anti-TSHR inhibitor, VRDN-292, is a potential best-in-class, half-life extended, monoclonal antibody that inhibits TSHR, designed for subcutaneous delivery in an autoinjector with the potential to support extended dosing intervals designed for patient convenience.

VRDN-292

 

Learn More About All Viridian Clinical Trials
View

TED Program Quote

Previous Next

Community
Corner

Learn more about Viridian’s
commitment to patients

View